The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

Aljazeera Hospital

Status: Unknown

Conditions: Antiphospholipid Syndrome in Pregnancy

Treatments: Diagnostic Test: Ultrasound with Doppler and 3D technology

Study type: Observational

Funder types: Other

Identifiers

NCT03505840

vocal in placenta

Details and patient eligibility

About

Antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Full description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Singleton pregnancy.

  • Gestational age of 34-37 weeks.
  • Pregnant women with antiphospholipid syndrome

Exclusion criteria

• Twin or multiple pregnancies.
• Congenital fetal anomalies.
• Gestational age of less than 34.
• Gestational age of more than 37.
• Women with placental or umbilical artery anomalies.
• Antepartum hemorrhage (placental abruption, placenta previa and vasa previa).
• Posterior placenta.
• History of rupture of membrane.
• Patient refusal or fall outs.

Trial design

100 participants in 2 patient groups

antiphospholipid group

Description:

pregnant ladies in the third trimester who have antiphospholipid syndrome

Treatment:

Diagnostic Test: Ultrasound with Doppler and 3D technology

control group

Description:

pregnant ladies in the third trimester who have no medical disorders with pregnancy

Treatment:

Diagnostic Test: Ultrasound with Doppler and 3D technology